InvestorsHub Logo
Followers 7
Posts 1577
Boards Moderated 0
Alias Born 02/27/2014

Re: turokman post# 75683

Sunday, 05/17/2015 12:22:48 PM

Sunday, May 17, 2015 12:22:48 PM

Post# of 80868
the stock would probably be up another 100% with any change in governance and compensation practices at this company.

Lets face it, the stock is still undervalued.....the problem is that the threat to shareholder value of keeping most of executives' pay in stocks is worrisome. By 2016, the company has run a few years with plus 10% dilution for stock grants.....so, the impressive stock grants of the past should be more than enough to motivate any reasonable human being to perform, in particular if stocks are vested over 4 years.
Probelm here can only be that the unvested stock grants of executives are vested when the executive leaves....Something that seems to be very shareholder unfriendly, and forcing the company to focus more on revenue growth than profitability to keep on printing more stocks to retain employees.

It's a peculiar governance and compensation to say the least. It might work, and Musclepharm may become a billion dollar company in a short time....or it might all fall apart next year, as promised revenue growth doesn't materialize whatsoever in Q3 and Q4, and the executives would have gotten lots of stocks for not performing well at all, by not meeting any of it's own targets.